A press release issued through PR Newswire says Hello Dose, a Brooklyn-based clinician-led telehealth weight management practice, is running a series of no-cost public webinars on GLP-1 medications, metabolic health, longevity, hormone replacement therapy and peptide therapy.

The sessions are led by founder Bracha Banayan, FNP, held on select Monday evenings, and open to anyone, including people who are not Hello Dose patients. GLP-1 receptor agonists are the drug class that includes semaglutide, used in type 2 diabetes treatment and medical weight management.

The founder's own story

Banayan says she gained roughly 20 pounds during the COVID-19 pandemic and could not lose it through diet and exercise alone. She describes herself as initially skeptical of GLP-1 medications before deciding to try semaglutide under medical care.

That experience, she says, pushed her toward the wider picture: glucose regulation, insulin, inflammation, muscle, nutrition and long-term metabolic health. "There is a much bigger conversation here than simply losing weight," she said in the release.

What the sessions cover

The listed topics run well past the prescription pad: glucose and insulin regulation, food choices, building and maintaining muscle during weight loss, physical activity, sleep and stress management. The framing is that medication is one tool rather than the whole answer, which is a more honest pitch than most of this category manages.

Peptide therapy and hormone replacement get their own treatment, and the release is specific about the angle: what is currently known, where research is still evolving, and why decisions should be individualized with a qualified provider. Banayan also pushes back on longevity being reduced to a single medication or supplement.

The part worth naming

This is a press release from a practice that prescribes the therapies it is teaching people about. Free education from a seller is still marketing, however good the content, and the release itself notes that Hello Dose programs may incorporate GLP-1 therapy.

No attendance figures, outcome data or published research appear anywhere in the announcement. It is an announcement of a schedule, not evidence of anything.

Bottom line

Banayan's stated goal is helping people ask better questions of their own providers rather than convincing anyone they need a particular treatment. Whether a vendor-run webinar can consistently hold that line is the open question, and the release offers nothing to settle it.